SCHEMBL1904103

SCHEMBL1904103

Cc1noc(C)c1-c1ccc2c(NCc3ccccc3)c(N)cnc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 8/20 0.58
LMNA P02545 8/20 0.58
CYP1A2 P05177 6/20 0.58
CYP2D6 P10635 4/20 0.58
CYP2C19 P33261 4/20 0.58
TSHR P16473 4/20 0.58
ALDH1A1 P00352 3/20 0.58
HIF1A Q16665 2/20 0.58
KDM4E B2RXH2 2/20 0.58
HPGD P15428 2/20 0.58
MAPK1 P28482 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
HSD17B10 Q99714 1/20 0.58
CYP2C9 P11712 5/20 0.56
BRD4 O60885 6/20 0.52
BRD2 P25440 4/20 0.52
BRD3 Q15059 4/20 0.52
CLK4 Q9HAZ1 3/20 0.49
USP2 O75604 2/20 0.49
SLC2A1 P11166 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619284 0.81 LMNA (0.59) CYP3A4LMNACYP1A2CYP2D6CYP2C19
SCHEMBL16619289 0.81 LMNA (0.59) CYP3A4LMNACYP1A2CYP2D6CYP2C19
SCHEMBL17807882 0.78 BRD4 (0.61) CYP3A4LMNACYP1A2CYP2D6CYP2C19
SCHEMBL12168779 0.77 CYP3A4 (0.76) CYP3A4LMNACYP1A2ALDH1A1CYP2C9
SCHEMBL17813563 0.74 CYP1A2 (0.63) CYP3A4LMNACYP1A2CYP2D6CYP2C19
SCHEMBL17807857 0.74 CYP1A2 (0.54) CYP3A4LMNACYP1A2CYP2D6CYP2C19
SCHEMBL17807861 0.74 CYP1A2 (0.58) CYP3A4LMNACYP1A2CYP2D6CYP2C19
SCHEMBL213063 0.73 KMT2A (0.63) LMNATSHRALDH1A1KDM4EMAPK1
SCHEMBL15972881 0.73 LMNA (0.50) CYP3A4LMNACYP1A2CYP2C19CYP2C9
SCHEMBL12168791 0.73 BRD4 (0.49) CYP3A4CYP1A2CYP2C19ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496576-B1 IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-12-18 EP disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
EP-2496576-A1 IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
WO-2011054846-A1 IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors BRD4, BRD3, BRPF3 CYP3A4 1579/4885LMNA 1951/4885CYP1A2 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.